Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889155 | 0.87 | GPR119 (0.53) | GPR119TBK1FAAH | |
| SCHEMBL389866 | 0.82 | GPR119 (0.46) | GPR119TBK1KDM4EPKMLIMK2 | |
| SCHEMBL5399943 | 0.82 | GPR119 (0.45) | GPR119FAAHKDM4EPKMLIMK2 | |
| SCHEMBL5399734 | 0.80 | FAAH (0.47) | GPR119TBK1FAAHKDM4EPKM | |
| SCHEMBL390655 | 0.79 | TBK1 (0.46) | GPR119TBK1KDM4ELIMK2 | |
| SCHEMBL391299 | 0.79 | GPR119 (0.46) | GPR119TBK1KDM4EPKMLIMK2 | |
| SCHEMBL390308 | 0.79 | TBK1 (0.46) | GPR119TBK1LIMK2 | |
| SCHEMBL27747830 | 0.79 | GPR119 (0.49) | GPR119TBK1LIMK2 | |
| SCHEMBL391077 | 0.79 | TBK1 (0.47) | GPR119TBK1KDM4EPKMLIMK2 | |
| SCHEMBL388956 | 0.79 | GPR119 (0.46) | GPR119TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101870690-A | The prevention and the treatment that are substituted aryl and heteroaryl derivative and associated conditions thereof as metabolism regulators | ARENA PHARM INC | 2010-10-27 | — | — | CN | disclosed |
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1756084-B1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-11-26 | — | — | EP | disclosed |
| CN-1997640-A | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto | ARENA PHARM INC (US) | 2007-07-11 | — | — | CN | disclosed |
| EP-1756084-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121121-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP11B1 | GPR119 31/4885TBK1 4689/4885FAAH 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.